G23.1

Progressive Supranuclear Ophthalmoplegia [Steele-Richardson-Olszewski] (ICD-10-CM G23.1)

Focused guidance for Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski] under code G23.1, designed to support clear triage language and continuity of neurological care.

Sam Tuffun , PT, DPT
Expertise in rehabilitation, outpatient care, and the intricacies of medical coding and billing.

Overview

Progressive Supranuclear Ophthalmoplegia [Steele-Richardson-Olszewski] (G23.1) is less about labeling a chart and more about connecting pattern recognition to safe next actions, in a way that supports decisions for G23.1.

For YMYL reliability, ambiguity should be minimized in escalation instructions and follow-up timing, so the note remains actionable for G23.1.

Concise, evidence-linked wording usually outperforms broad narrative for safety and billing alignment, and this helps keep follow-up plans safer for G23.1.

Local protocols and clinician judgment remain the final authority when risk changes quickly, framed around the current G23.1 encounter.

Symptoms

Ask what changed first, what changed most recently, and what the patient considers the main current limitation, a detail that improves chart clarity for G23.1.

Functional impact on driving, work, school, or self-care should be documented as a clinical outcome, not a side note, something that usually alters follow-up cadence in G23.1.

Pair subjective symptoms with objective findings whenever possible to reduce drift between visits, especially useful when counseling patients about G23.1.

For G23.1, symptom review should capture onset speed, progression pattern, and impact on routine activities, a detail that improves chart clarity for G23.1.

Causes

When causation is uncertain, document what evidence supports each leading option and what evidence is still missing, a practical triage signal within extrapyramidal and movement disorders (g20-g26) for G23.1.

Likely causes for G23.1 should be ranked by plausibility and consequence, not listed as an unprioritized checklist, which often changes next-visit planning for G23.1.

In recurrent presentations, compare the current pattern to historical baseline rather than treating each event as isolated, especially useful when counseling patients about G23.1.

Primary neurologic mechanisms may coexist with metabolic, medication, vascular, inflammatory, or infectious contributors, something that usually alters follow-up cadence in G23.1.

Diagnosis

When tests are deferred, include rationale and explicit criteria for when testing should be revisited, which often changes next-visit planning for G23.1.

Nondiagnostic first-pass workups should end with timed reassessment plans, not open-ended observation, a practical triage signal within extrapyramidal and movement disorders (g20-g26) for G23.1.

Chart quality improves when ordered and non-ordered investigations are both explained, something that usually alters follow-up cadence in G23.1.

Imaging, electrophysiology, sleep testing, or labs should be justified by differential priorities, not habit, especially useful when counseling patients about G23.1.

Differential Diagnosis

Differential diagnosis for G23.1 should balance probability with harm if a diagnosis is missed, a detail that improves chart clarity for G23.1.

When uncertainty persists, define what new finding would re-rank the top possibilities, a detail that improves chart clarity for G23.1.

In evolving presentations, serial differential updates are usually safer than premature closure, especially useful when counseling patients about G23.1.

Ranking should be revised as data arrives to avoid anchoring on the first impression, a practical triage signal within extrapyramidal and movement disorders (g20-g26) for G23.1.

Prevention

Medication reconciliation at every transition can prevent avoidable neurologic deterioration, something that usually alters follow-up cadence in G23.1.

Prevention improves when responsibilities are explicit for patient, caregiver, and clinical team, something that usually alters follow-up cadence in G23.1.

Follow-up timing should match risk level, not scheduling convenience, and helpful for safer handoff notes linked to G23.1.

Long-term prevention is more realistic when integrated into daily routines rather than idealized plans, a practical triage signal within extrapyramidal and movement disorders (g20-g26) for G23.1.

Prognosis

Realistic prognosis framing reduces anxiety and improves adherence to monitoring plans, which often changes next-visit planning for G23.1.

Prognosis in G23.1 depends on etiology, baseline reserve, treatment timing, and follow-up continuity, especially useful when counseling patients about G23.1.

If trajectory plateaus or worsens, revisit working assumptions early, which often changes next-visit planning for G23.1.

Prognosis should be revised as new objective data emerges, not frozen at first diagnosis, which often changes next-visit planning for G23.1.

Red Flags

Return instructions should specify symptoms, urgency level, and where to seek care, which often changes next-visit planning for G23.1.

If high-risk signs appear, delay in escalation can be more harmful than over-triage, something that usually alters follow-up cadence in G23.1.

Care plans should include caregiver-facing red flags for situations where the patient may not self-identify deterioration, a detail that improves chart clarity for G23.1.

Emergency criteria should be written in plain language, not only coded terminology, a detail that improves chart clarity for G23.1.

Risk Factors

Baseline cognitive status, fall risk, and caregiver availability meaningfully change outpatient safety planning, which often changes next-visit planning for G23.1.

Social determinants such as transport limits, fragmented care, or low support at home can increase adverse-event risk, a practical triage signal within extrapyramidal and movement disorders (g20-g26) for G23.1.

Risk documentation is most useful when linked directly to monitoring interval and escalation thresholds, which often changes next-visit planning for G23.1.

If recent hospitalization or medication change occurred, reassess risk before keeping prior follow-up cadence, which often changes next-visit planning for G23.1.

Treatment

A treatment plan is stronger when it states both what to do now and what to do if progress stalls, something that usually alters follow-up cadence in G23.1.

Medication choices should reflect symptom pattern, comorbidity profile, and tolerability history, something that usually alters follow-up cadence in G23.1.

Non-pharmacologic supports (sleep, rehabilitation, behavioral strategies, caregiver coaching) often influence outcomes substantially, something that usually alters follow-up cadence in G23.1.

Complex cases benefit from coordinated plans across neurology, primary care, rehabilitation, and behavioral health, which often changes next-visit planning for G23.1.

Medical References

NINDS overview relevant to Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski] (coding variant G 23 1)
CDC prevention and safety resources for Extrapyramidal and movement disorders (G20-G26) in Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski] presentations (coding variant G 23 1)
WHO ICD-10 classification notes for Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski] and related diagnoses (variant G 23 1)
AHRQ documentation and care-transition guidance for Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski] in neurology workflows (coding variant G 23 1)
Specialty society guidance for clinical management of Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski] with Extrapyramidal and movement disorders (G20-G26) context (coding variant G 23 1)

Got questions? We’ve got answers.

Need more help? Reach out to us.

When is G23.1 the right code to use? (Progressive Supranuclear Ophthalmoplegia [Steele-Richardson-Olszewski]; coding variant G 23 1)
When is additional testing justified? (Progressive Supranuclear Ophthalmoplegia [Steele-Richardson-Olszewski]; coding variant G 23 1)
How can relapse risk be reduced over time? (Progressive Supranuclear Ophthalmoplegia [Steele-Richardson-Olszewski]; coding variant G 23 1)
How can clinicians avoid vague coding language? (Progressive Supranuclear Ophthalmoplegia [Steele-Richardson-Olszewski]; coding variant G 23 1)
How can recovery be tracked safely between appointments? (Progressive Supranuclear Ophthalmoplegia [Steele-Richardson-Olszewski]; coding variant G 23 1)